Atherothrombotic stroke in non-valvular atrial fibrillation
https://doi.org/10.14412/2074-2711-2019-3S-78-81
Abstract
The review analyzes data on the detection rate of and the abilities to predict and prevent non-cardioembolic strokes in non-valvular atrial fibrillation. According to accumulated facts, vitamin K antagonists in non-valvular atrial fibrillation are noted to be inferior to antiplatelet drugs in efficiency in preventing non-cardioembolic (atherothrombotic in particular) strokes, and the widespread use of oral anticoagulants in combination with antiplatelet drugs does not generally reduce the incidence of poor outcomes, markedly increasing the risk of serious bleeding. Nevertheless, it is conceivable that this combination antithrombotic therapy may be useful for certain categories of patients at the highest risk for atherothrombotic stroke and at relatively low risk for hemorrhagic complications. Cohorts of patients, to whom such an approach should be reasonable considered to be applied, have not yet been identified.
About the Authors
I. S. Yavelov
National Medical Research Center of Preventive Medicine, Ministry of Health of Russia
Russian Federation
10, Petroverigsky Lane, Build. 3, Moscow 101990
Russian Federation
10, Petroverigsky Lane, Build. 3, Moscow 101990
E. Yu. Okshina
National Medical Research Center of Preventive Medicine, Ministry of Health of Russia
Russian Federation
10, Petroverigsky Lane, Build. 3, Moscow 101990
Russian Federation
10, Petroverigsky Lane, Build. 3, Moscow 101990
References
1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi: 10.1093/eurheartj/ehw210
2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC. 2019. doi: 10.1016/j.jacc.2019.01.011
3. Kim YD, Cha MJ, Kim J, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke. 2011;42:930-4. doi: 10.1161/STROKEAHA.110.602987
4. Arboix A, Garcia-Eroles L, Massons JB, et al. Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J Cardiol. 2000;73:33-42. doi: 10.1016/S0167-5273(99)00214-4
5. Benbir G, Uluduz D, Ince B, Bozluolcay M. Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg. 2007;109:485-90. doi: 10.1016/j.clineuro.2007. 03.009
6. Bogousslavsky J, van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990;40:1046-50. doi: 10.1212/WNL.40.7.1046
7. Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39-43. doi: 10.1159/000016023
8. Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2002; 13:16-20. doi: 10.1159/000047740
9. Park YS, Chung PW, Kim YB, et al. Small deep infarction in patients with atrial fibrillation: evidence of lacunar pathogenesis. Cerebrovasc Dis. 2013;36:205-10. doi: 10.1159/000353736
10. Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke. 2000;31:2106-11. doi: 10.1161/01.STR.31.9.2106
11. Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke. 2001;32:2828-32. doi: 10.1161/hs1201.099520
12. Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic stroke in patients with atrial fibrillation. Angiology. 2019;70:299-304. doi: 10.1177/0003319718791711
13. Cano LM, Cardona P, Quesada H, et al. Ischaemic stroke in patients treated with oral anticoagulants. Neurologia. 2016;31:395-400. doi: 10.1016/j.nrl.2014.09.010
14. Hwang J, Chung J-W, Lee MJ, et al. Implications of CHA2DS2-VASc Score in Stroke Patients with Atrial Fibrillation: An Analysis of 938 Korean Patients. Eur Neurol. 2017;77:307- 15. doi: 10.1159/000475495
15. Kim SJ, Ryoo S, Kwon S, et al. Is atrial fibrillation always a culprit of stroke inpatients with atrial fibrillation plus stroke? Cerebrovasc Dis. 2013;36:373-82. doi: 10.1159/000355571
16. Cha M-J, Kim YD, Nam HS, et al. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2DS2-VASc scores. Eur J Neurol. 2012; 19:473-9. doi: 10.1111/j.1468-1331.2011.03547.x
17. Yang P-S, Pak H-N, Park D-H, et al. Noncardioembolic risk factors in atrial fibrillationassociated ischemic stroke. PLoS ONE. 2018; 13:e0201062. doi: 10.1371/journal.pone.0201062
18. Bekwelem W, Jensen PN, Norby FL, et al. Carotid atherosclerosis and stroke in atrial fibrillation: the atherosclerosis risk in Communities study. Stroke. 2016;47:1643-46. doi: 10.1161/STROKEAHA.116.013133
19. Paciaroni M, Agnelli G, Ageno W, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis. 2010;212:564-6. doi: 10.1016/j.atherosclerosis.2010.06.016
20. Miller VT, Pearce LA, Feinberg WM, et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke prevention in atrial fibrillation investigators. Neurology. 1996;46:238-40. doi: 10.1212/WNL.46.1.238
21. Becattini C, Dentali F, Camporese G, et al. Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis. 2018; 271:177-81. doi: 10.1016/j.atherosclerosis.2018.02.004
22. Lane DA, Raichand S, Moore D, et al. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. Health Technol Assess. 2013; 17(30). doi: 10.3310/hta17300
23. Kumar S, Danik SB, Altman RK, et al. NonVKA Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients with Atrial Fibrillation: a Meta-analysis of Randomized Controlled Trials. Cardiol Rev. 2016;24: 218-23. doi: 10.1097/CRD.0000000000000088
24. Masunaga N, Abe M, Ogawa H, et al. Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation. The Fushimi AF Registry. Circ J. 2018;82:2983-91. doi: 10.1253/circj.CJ-18-0872
25. Steinberg BA, Kim S, Piccini JP, et al. Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry. Circulation. 2013;128:721-8. doi: 10.1161/CIRCULATIONAHA.113.002927
26. Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106:739-49. doi: 10.1160/TH11-05-0364
27. Nakamura A, Kuroda J, Ago T, et al. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation. Cerebrovasc Dis. 2016;42: 196-204. doi: 10.1159/000445723
28. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. NEJM. 2017;377:1319-30. doi: 10.1056/NEJMoa1709118
29. Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139:1134-45. doi: 10.1161/ CIRCULATIONAHA.118.035864
Review
For citations:
Yavelov I.S., Okshina E.Yu. Atherothrombotic stroke in non-valvular atrial fibrillation. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):78-81. (In Russ.) https://doi.org/10.14412/2074-2711-2019-3S-78-81
Views: 579
Email this article 